Term
|
Definition
| Short acting beta agonist |
|
|
Term
|
Definition
| Most effective drug for acute bronchoconstriction |
|
|
Term
|
Definition
| Overuse of this asthma drug may lead to increased mortality because of receptor desensitization |
|
|
Term
|
Definition
| Long acting beta2 selective agonist with a SLOW onset |
|
|
Term
|
Definition
| Long acting beta2 agonist with a RAPID onset |
|
|
Term
|
Definition
| This allows the long acting beta2 agonists to repeatedly and persistantly activate the receptor |
|
|
Term
|
Definition
| Used for maintanance therapy of pts w/ nocturnal sx |
|
|
Term
|
Definition
| Used for maintenance and prevention of exercise-induced bronchospasm and for COPD |
|
|
Term
|
Definition
| This drug inhibits phosphodiesterase, leading to increased cAMP |
|
|
Term
|
Definition
| This drug uses PDE4 as a critical isoenzyme |
|
|
Term
|
Definition
| This drug has antagonist action at bronchoconstrictor adenosine receptors |
|
|
Term
|
Definition
| This drug has effects on calcium release mechanisms involved in muscle contraction |
|
|
Term
|
Definition
| This drug induces histone deacetylase |
|
|
Term
|
Definition
| Plasma levels of this drug must be monitored because of many food/drug interactions that decrease its concentration, and also bc of hypokalemia |
|
|
Term
| Ipratropium bromide or Tiotropium |
|
Definition
| An anticholinergic agent that is a derivative of atropine, so blocks muscarinic receptors |
|
|
Term
|
Definition
| THis drug targets M3 receptors to reduce vagal-stimulated bronchoconstriction |
|
|
Term
|
Definition
| This anticholinergic agent is approved for once daily COPD therapy |
|
|
Term
| Ipratropium or Tiotropium |
|
Definition
| This drug can cause dry mouth and pharynx and increased occular pressure |
|
|
Term
|
Definition
| This drug is approved for use in COPD, but is not approved for use in asthma (though it is still used occasionaly) |
|
|
Term
|
Definition
| Patients on this can develop "steroid-resistant" asthma |
|
|
Term
|
Definition
| Side effects include suppression of hypothalamic-pituitary-adrenal axis |
|
|
Term
|
Definition
| Long term use leads to decreased bone density and osteoporosis |
|
|
Term
|
Definition
| Caution must be used when tapering and switching forms (inhaled to systemic or vice versa) |
|
|
Term
|
Definition
| A selective and competitive antagonist of CYstTL3, the major leukotriene in D4 |
|
|
Term
|
Definition
| Has an important role in ASA asthma |
|
|
Term
|
Definition
| Carries a risk of psychosis or depression |
|
|
Term
|
Definition
| A selective inhibitor of 5-lipoxygenase enzyme |
|
|
Term
|
Definition
| Blocks all leukotriene effects, so has more anti-inflamm activity than leukotriene |
|
|
Term
|
Definition
| Stabilizes mast cells to prevent release of mediators and alters chloride channel fx |
|
|
Term
|
Definition
| Used to decrease airway hyperresponsiveness |
|
|
Term
|
Definition
| Can lead to reflex wheezing |
|
|
Term
|
Definition
| An antibody to IgE-prevents the IgE from binding to receptors on mast cells and causing degranulation |
|
|
Term
|
Definition
| Possible cardiac, stroke, and anaphylactic rxns |
|
|
Term
|
Definition
| Used in moderate to severe asthma with reactivity to allergens and whose sx are not controlled by inhaled steroids |
|
|
